

Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029

<https://marketpublishers.com/r/G746DD7648B8EN.html>

Date: February 2023

Pages: 240

Price: US\$ 3,000.00 (Single User License)

ID: G746DD7648B8EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:

Global KRAS Inhibitors Market Opportunity > USD 4 Billion By 2029
200%

Number Of Approved Drugs: 2 Drugs

Approved Drug Global & Regional Sales Insight

Approved Drugs Patent, Price & Dosage Analysis

Regional Analysis: USA, UK, China Europe, Japan, South Korea

Number Of Drugs In Clinical Trials: > 60 Drugs

Insight On All Drugs In Clinical Trials By Phase, Company, Country, Indication & Patient Segment

The advancement in the field of biology has led to the discovery of several oncogenes that play a critical role in cancer development and thus presenting researchers with opportunities to target them. KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for

possibly development of novel KRAS inhibitors. The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS.

Researchers over the world have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable. But after the approval of first ever KRAS inhibitor, Lumakras (Sotorasib) developed by Amgen in 2021 for treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer, the product market showed significant growth in terms of both commercial sale success and enhanced overall survival rates. Its sales grew more than twice in 2022 as compare to 2021 levels. The drug is the first ever targeted anti-cancer treatment drug against KRAS mutations.

Furthermore, Qiagen also launched Therascreen KRAS RGQ PCR Kit after it received US regulatory approval as a companion diagnostic in aiding the diagnosis of non-small cell lung cancer. This was the first companion diagnostic kit to have received premarket approval from the US FDA. Nevertheless, additional progress has been made in the industry and FDA has further approved companion diagnosis kits. In December, 2022 Agilent Resolution's ctDx FIRST was granted approval by the FDA as a companion diagnostic for patients with NSCLC.

The ever increasing cases of cancer and the ability of the tumor to develop new and frequent mutations signifies an unmet need for advancement of novel therapies in the management and treatment of cancer. However, with discoveries like that of Kristen rat sarcoma viral oncogene homolog (KRAS), the future of cancer targeted therapies is something to look forwards. It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer.

With booming research and development strategies, pharmaceutical companies are rapidly moving forward and aiming this oncogene. Recently, VITRAC Therapeutic has initiated a phase I clinical trial with AURKA Inhibitor VIC-1911 and Sotorasib a G12C inhibitor for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). This study of VIC-1911 as monotherapy and in combination with Sotorasib is being performed at Yale Cancer Centre. The preclinical studies have strongly supported the combinational use of both the drugs and by using this multi-targeted approach, the study aims to provide a more effective therapeutic outcome for patients with KRAS G12C-mutated NSCLC.

The market for KRAS targeted drugs is poised with exponential growth with several

factors determining its potential. The KRAS market is widely supported by accelerating trend of preclinical and in vitro studies which has increased the number of patients that are seeking out treatment opportunities. The rising demand for this therapy has resulted in increasing acceptance of cancer managing treatments. The market expects new medications to swiftly and rapidly enter the commercial sector.

There are also factors that will be challenging the future potential of this market. With increased research and development activity, there also increases the number of competitors in the market. Drug manufacturers need to develop medications that have innovation and creativeness and the ability to show better outcomes than its opponents. Currently, Amgen is in the lead for KRAS targeted therapy market but with the incoming of more drugs in the future, some challenges are bound to be faced by the company if it wants to keep its position as the topmost stakeholder in the KRAS inhibitors drug market.

For instance, on December 2022, the US FDA granted accelerated approval to Mirati Therapeutics' Adagrasib (Krazati) which is a RAS GTPase family inhibitor for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. This approval was based on KRYSTAL-1, a multicenter, open label clinical trial and the indication was approved under accelerated approval based on the overall response rate and duration of response.

This report aims to provide an in depth analysis about the current market scenario of KRAS targeted therapies and the future potential this segment holds. Overall, as per our analysis, the market for KRAS inhibitors will see an exponential growth mainly attributed by the robust research and development activities in this domain as well as the presence of strong clinical pipeline of drugs candidates. The report sheds light on the factors that will propel the markets growth as well as factors that will be challenging the market opportunity.

Contents

1. INTRODUCTION TO KRAS INHIBITORS

- 1.1 Development of KRAS Inhibitors
- 1.2 Mechanism Of Action

2. ROLE OF KRAS INHIBITORS IN CANCER THERAPY

- 2.1 Lung Cancer
- 2.2 Pancreatic Cancer
- 2.3 Colorectal Cancer
- 2.4 Other Cancers

3. LUMAKRAS – FIRST APPROVED KRAS INHIBITOR

- 3.1 Overview & Patent Insight
- 3.2 Dosage & Price Analysis
- 3.3 Sales Analysis

4. KRAZATI - SECOND APPROVED KRAS INHIBITOR

- 4.1 Overview & Patent Insight
- 4.2 Dosage & Price Analysis

5. GLOBAL KRAS INHIBITOR MARKET OUTLOOK

- 5.1 Current Market Scenario
- 5.2 Future Market Opportunity

6. KRAS INHIBITOR MARKET REGIONAL ANALYSIS

- 6.1 US
- 6.2 UK
- 6.3 China
- 6.4 Europe
- 6.5 Japan
- 6.6 South Korea
- 6.7 Canada

7. GLOBAL KRAS INHIBITORS CLINICAL PIPELINE OVERVIEW

- 7.1 By Country
- 7.2 By Phase
- 7.3 By Company
- 7.4 By Indication
- 7.5 By Patient Segment

8. GLOBAL KRAS INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Phase-I
- 8.4 Phase-I/II
- 8.5 Phase-II
- 8.6 Phase-III

9. MARKETED KRAS INHIBITORS CLINICAL INSIGHT

- 9.1 Sotorasib - Amgen
- 9.2 Adagrasib - Mirati Therapeutics

10. GLOBAL KRAS INHIBITORS MARKET DYNAMICS

- 10.1 Market Drivers & Opportunities for KRAS Inhibitors
- 10.2 Challenges for KRAS Inhibitors Market

11. COMPETITIVE LANDSCAPE

- 11.1 Array BioPharma
- 11.2 Applied Pharmaceutical Science
- 11.3 Amgen
- 11.4 AnBogen Therapeutics
- 11.5 Ascentage Pharma
- 11.6 AstraZeneca
- 11.7 BridgeBio Pharma
- 11.8 Boehringer Ingelheim

- 11.9 Erasca
- 11.10 Carmot Therapeutics
- 11.11 FogPharma
- 11.12 Frontier Medicines
- 11.13 Jacobio Pharmaceuticals
- 11.14 Jemincare
- 11.15 Jiangsu Hansoh Pharmaceutical
- 11.16 Jiangsu Hengrui Medicine Co.
- 11.17 Leidos Biomedical Research
- 11.18 Mirati Therapeutics
- 11.19 REVOLUTION Medicines
- 11.20 Roche
- 11.21 Shanghai Euregen Biopharma
- 11.22 Shanghai Yingli Pharmaceutical
- 11.23 Singh Biotechnology
- 11.24 Suzhou Genhouse Bio
- 11.25 Suzhou Zelgen Biopharmaceuticals

List Of Figures

LIST OF FIGURES

Figure 1-1: RAS Mutation – Frequency of KRAS Mutation v/s HRAS & NRAS Mutations

Figure 1-2: Historical Development of KRAS Inhibitors

Figure 1-3: General Mechanism of KRAS Inhibitors against Cancer

Figure 1-4: Targeting Approaches of KRAS Inhibitors

Figure 1-5: Direct Targeting of Mutant KRAS

Figure 1-6: Targets for Modifying the KRAS Membrane Association

Figure 2-1: KRAS Mutational Frequency by Organs (%)

Figure 2-2: Roles of KRAS Inhibitors in Cancer Treatment

Figure 2-3: Global – Estimated Newly Diagnosed Lung Cancer Cases & Deaths (Millions), 2020

Figure 2-4: Global – Lung Cancer Incidence by Type (%), 2020

Figure 2-5: Impact of KRAS Inhibitor on Lung Cancer

Figure 2-6: Investigational KRAS Inhibitors for Lung Cancer

Figure 2-7: RMC-6291 Phase I Trial – Study Initiation & Expected Completion Year

Figure 2-8: Revolution Medicines – KRAS inhibitors & Status

Figure 2-9: JAB-21822 Phase I/II Monotherapy Trial – Study Initiation & Expected Completion Year

Figure 2-10: JAB-21822 Phase I/II Monotherapy & Combination Therapy Trial – Study Initiation & Expected Completion Year

Figure 2-11: JAB-21822 Phase I/II Combination Therapy Trial – Study Initiation & Expected Completion Year

Figure 2-12: JAB-21822 Phase I/II Co Mutation Trial – Study Initiation & Expected Completion Year

Figure 2-13: Global – Estimated Newly Diagnosed Pancreatic Cancer Cases & Deaths, 2020

Figure 2-14: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer

Figure 2-15: Role of KRAS Inhibitors in Pancreatic Cancer

Figure 2-16: Investigational KRAS Inhibitors for Pancreatic Cancer

Figure 2-17: siG12D LODER Phase II Trial – Study Initiation & Expected Completion Year

Figure 2-18: iExosomes Phase I Trial – Study Initiation & Expected Completion Year

Figure 2-19: HBI-2438 Phase I Trials – Study Initiation & Expected Completion Year

Figure 2-20: KRAS mTCR PBL Phase I/II Trials – Study Initiation & Expected Completion Year

Figure 2-21: Global – Estimated Newly Diagnosed Colorectal Cancer Cases & Deaths

(Millions), 2020

Figure 2-22: Global – New Colorectal Cancer Incidences By Type (%), 2020

Figure 2-23: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer

Figure 2-24: Investigational KRAS Inhibitors for Colorectal Cancer

Figure 2-25: KRAS mTCR PBL Phase I/II Trials – Study Initiation & Expected Completion Year

Figure 2-26: IBI351 Phase Ib Trial – Study Initiation & Expected Completion Year

Figure 2-27: Global – Estimated Newly Diagnosed Leukemia & Lymphoma Cases & Deaths (Millions), 2020

Figure 2-28: US – Estimated New Hodgkin and Non Hodgkin Lymphoma Cases & Deaths (Millions), 2022

Figure 2-29: Frequency of KRAS Mutation in Hematological Cancer (%)

Figure 2-30: Global – Newly Diagnosed Prostate Cancer Cases & Deaths (Millions), 2020

Figure 2-31: Global – Number of Newly Diagnosed Gastric Cancer Cases & Deaths (Millions), 2020

Figure 2-32: Global – Number of Newly Diagnosed Endometrial Cancer Cases & Deaths (Millions), 2020

Figure 2-33: Global – Gynecological Cancer Incidence By Type, 2020

Figure 2-34: Global – Newly Diagnosed Cases & Deaths related to Brain Cancer (Millions), 2020

Figure 3-1: Lumakras – Approval Year By Region

Figure 3-2: US – Lumakras Patent Filing & Expiration Year

Figure 3-3: US - Lumakras FDA Approval & Patent Exclusivity Year

Figure 3-4: US – Number Of Physicians Prescribing Lumakras Annually, 2021 & 2022

Figure 3-5: US – Number Of Patients Getting Prescribed Lumakras Annually, 2021 & 2022

Figure 3-6: US – Number Of Physicians Prescribing Lumakras Annually Quarterly, 2022

Figure 3-7: US – Number Of Patients Getting Prescribed Lumakras Quarterly, 2022

Figure 3-8: US - Price for 240 Tablet Lumakras Supply & Price Per Unit of 120mg Tablet (US\$), February'2023

Figure 3-9: UK - Price for 240 Tablet Lumakras Supply & Price Per Unit of 120mg Tablet (GBP/US\$), February'2023

Figure 3-10: US - Monthly & Annual Treatment Cost with Lumakras (US\$), February'2023

Figure 3-11: Lumakras – Recommended Initial & Reduced Dose (mg/day)

Figure 3-12: Global – Lumakras/Lumykras Annual Sales (US\$ Million), 2021-2022

Figure 3-13: Global – Lumakras/Lumykras Sales by Region (US\$ Million), 2022

Figure 3-14: Global – Lumakras/Lumykras Annual Sales by Region (%), 2022

Figure 3-15: Global – Lumakras/Lumykras Quarterly Sales (US\$ Million), 2022

Figure 3-16: US – Lumakras/Lumykras Annual Sales (US\$ Million), 2021 - 2022

Figure 3-17: US – Lumakras/Lumykras Quarterly Sales (US\$ Million), 2022

Figure 3-18: ROW – Lumakras/Lumykras Quarterly Sales (US\$ Million), 2022

Figure 4-1: US – Adagrasib Patent Filing & Publication Year

Figure 4-2: US – WAC Price for 180-Tablet Krazati Supply & Price Per Unit of 200mg Tablet (US\$), January'2023

Figure 4-3: Krazati – Recommended Initial & Reduced Dose (mg/day)

Figure 4-4: US – Estimated Monthly & Annual Treatment Cost with Krazati (US\$), January'2023

Figure 5-1: Global – Cancer Incidences & Deaths (Million), 2020

Figure 5-2: Global - KRAS Inhibitor Market (US\$ Million), 2021 & 2022

Figure 5-3: Global - KRAS Inhibitor Market Size by Region (US\$ Million), 2022

Figure 5-4: Global – KRAS Inhibitor Market Size (US\$ Million), 2023 - 2029

Figure 6-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 6-2: US vs. ROW – KRAS Inhibitor Market Size (US\$ Million), 2022

Figure 6-3: US vs. ROW – KRAS Inhibitor Market Size (%), 2022

Figure 6-4: US – KRAS Inhibitor Market Size (US\$ Million), 2022 - 2029

Figure 6-5: UK – Cancer Incidences & Deaths, 2020 & 2025

Figure 6-6: UK – KRAS Inhibitor Market Size (US\$ Million), 2022 - 2029

Figure 6-7: China – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 6-8: China – KRAS Inhibitor Market Size (US\$ Million), 2022 - 2029

Figure 6-9: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 6-10: Europe – KRAS Inhibitor Market Size (US\$ Million), 2022 - 2029

Figure 6-11: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 6-12: Japan – KRAS Inhibitor Market Size (US\$ Million), 2022 – 2029

Figure 6-13: South Korea – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 6-14: South Korea – KRAS Inhibitor Market Size (US\$ Million), 2022 – 2029

Figure 6-15: Canada – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 6-16: Canada – KRAS Inhibitor Market Size (US\$ Million), 2022 - 2029

Figure 7-1: Global - KRAS Protein inhibitors Clinical Trials by Country, 2023 -2029

Figure 7-2: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2023 -2029

Figure 7-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2023 -2029

Figure 7-4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2023 -2029

Figure 7-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2023 -2029

Figure 10-1: Drivers for KRAS Inhibitor Market

Figure 10-2: Challenges for KRAS Inhibitor Market

Figure 10-3: US – Estimated Monthly Treatment Cost of Lumakras & Krazati v/s Other

Cell Signal Targeting Therapeutics

I would like to order

Product name: Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029

Product link: <https://marketpublishers.com/r/G746DD7648B8EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G746DD7648B8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970